EVLV · Investment summary · as of 3 August 2026
Priced for an operating path the record does not support
Business type: Transition · scaling but economically observable
The operating path required by the price could not be established.
At $5.68, EVLV requires a 28% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 21%.
The growth side is the evidenced side (contracted, 1.9y RPO cover, guided). The entire disagreement with the market is whether a never-profitable business reaches ~18-24% EBIT margins. A growth-axis ranking would misfile this name (COHR precedent).
The value rests on an exit multiple of 18.0x, a terminal operating margin of 18% and a 12.7% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Composite stated loss -40%, combined probability ~0.55.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The growth side is the evidenced side (contracted, 1.9y RPO cover, guided). The entire disagreement with the market is whether a never-profitable business reaches ~18-24% EBIT margins. |
| What do we forecast? | Revenue growth of 21% demonstrated; a terminal operating margin of 18%; an exit multiple of 18.0x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is -50.7 percentage points. |
| What is it worth? | Twelve-month target $7.35, +29% from the struck price. Scenario-weighted expected return net of costs +29.3%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Date not announced — no dated event that would resolve the disagreement is on file
Composite stated loss -40%, combined probability ~0.55. Cause 1 - SEC enforcement / SDNY (p 0.30): order + penalties on an unremediated-controls company -> ~3x forward sales -> -43% ($3.24). Cause 2 - mix-shift exhaustion re-rate (p 0.25): reported growth falls to the ARR rate, hardware multiple applied -> -32%. Cause 3 - second restatement (p 0.10): five open material weaknesses, zero Q1'26 remediation progress, one covering exactly the lease-vs-purchase mechanics driving growth -> -60 to -65%. not a going-concern case: net cash $32.4m, positive Adjusted EBITDA, $92.3m deferred revenue already collected.
Estimated probability 55%, against the 25% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
On reaching the $7.35 target, re-run the 12-month build on then-current NTM estimates; trim if forward E[R] <= 0 net of costs. Any invalidation trigger re-rates the name regardless of price. On approach to the $7.35 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not determined | Is the operating path required by today's price achievable? Not established on the evidence on file. |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Composite stated loss -40%, combined probability ~0.55. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -50.7 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether the operating path today's price requires is achievable; the evidence does not settle it. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $5.00, which forces an immediate review.